TY - JOUR
T1 - Editorial – Musculoskeletal pain: Which role for tapentadol?
AU - Finco, G.
AU - Evangelista, Maurizio
AU - Marinangeli, F.
PY - 2019
Y1 - 2019
N2 - Chronic pain is defined as pain persisting after healing of an underlying pathology or as persisting
pain in the absence of tissue damage. In the last decade, the understanding of mechanisms involved in
chronic pain led to an improved approach to patient management, with the aim to reduce discomfort,
improve quality of life (QoL) and enhance functional recovery.
Chronic musculoskeletal pain, which is frequently encountered in clinical practice, can affect patients
of all ages and is particularly common in older patients. Indeed, low back pain is the most frequent
chronic pain condition worldwide, with a lifetime prevalence of >70% in western countries1,2. Neck pain
is also a common disabling disease, with a prevalence of 23%, and is associated with high costs for medical visits and physiotherapy. Both low back pain and neck pain involve nociceptive and neuropathic
pain mechanisms
AB - Chronic pain is defined as pain persisting after healing of an underlying pathology or as persisting
pain in the absence of tissue damage. In the last decade, the understanding of mechanisms involved in
chronic pain led to an improved approach to patient management, with the aim to reduce discomfort,
improve quality of life (QoL) and enhance functional recovery.
Chronic musculoskeletal pain, which is frequently encountered in clinical practice, can affect patients
of all ages and is particularly common in older patients. Indeed, low back pain is the most frequent
chronic pain condition worldwide, with a lifetime prevalence of >70% in western countries1,2. Neck pain
is also a common disabling disease, with a prevalence of 23%, and is associated with high costs for medical visits and physiotherapy. Both low back pain and neck pain involve nociceptive and neuropathic
pain mechanisms
KW - muscoloskeletal pain
KW - opioids
KW - tapentadol
KW - muscoloskeletal pain
KW - opioids
KW - tapentadol
UR - http://hdl.handle.net/10807/151702
UR - https://www.europeanreview.org/article/19379
U2 - 10.26355/eurrev_201911_19379
DO - 10.26355/eurrev_201911_19379
M3 - Editorial
SN - 1128-3602
VL - 23
SP - 1
EP - 4
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
ER -